CA3009149A1 - Formes cristallines polymorphes de l'acide obeticholique - Google Patents
Formes cristallines polymorphes de l'acide obeticholique Download PDFInfo
- Publication number
- CA3009149A1 CA3009149A1 CA3009149A CA3009149A CA3009149A1 CA 3009149 A1 CA3009149 A1 CA 3009149A1 CA 3009149 A CA3009149 A CA 3009149A CA 3009149 A CA3009149 A CA 3009149A CA 3009149 A1 CA3009149 A1 CA 3009149A1
- Authority
- CA
- Canada
- Prior art keywords
- obeticholic acid
- acid
- crystalline
- cholan
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des formes cristallines A, D, F, G et I de l'acide obéticholique. Ces formes cristallines sont utiles dans la production d'acide obéticholique (en particulier dans sa purification), qui est un médicament utile pour le traitement ou la prévention d'une maladie ou d'une affection, d'une maladie cardiovasculaire ou une maladie hépatique cholestatique médiées par le FXR et pour la réduction du cholestérol HDL, pour la diminution des triglycérides chez un mammifère ou pour l'inhibition de la fibrose.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/979,005 US9982008B2 (en) | 2012-06-19 | 2015-12-22 | Preparation and uses of obeticholic acid |
US14/979,005 | 2015-12-22 | ||
PCT/US2016/012651 WO2017111979A1 (fr) | 2015-12-22 | 2016-01-08 | Formes cristallines polymorphes de l'acide obéticholique |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3009149A1 true CA3009149A1 (fr) | 2017-06-29 |
Family
ID=55650649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3009149A Abandoned CA3009149A1 (fr) | 2015-12-22 | 2016-01-08 | Formes cristallines polymorphes de l'acide obeticholique |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP3394081A1 (fr) |
JP (1) | JP2018538331A (fr) |
KR (1) | KR20180095070A (fr) |
CN (1) | CN108495858A (fr) |
AU (1) | AU2016375566A1 (fr) |
BR (1) | BR112018012590A2 (fr) |
CA (1) | CA3009149A1 (fr) |
CL (1) | CL2018001720A1 (fr) |
CO (1) | CO2018006701A2 (fr) |
EA (1) | EA201891491A1 (fr) |
IL (1) | IL259998A (fr) |
MX (1) | MX2018007776A (fr) |
PH (1) | PH12018501318A1 (fr) |
SG (1) | SG11201805235XA (fr) |
WO (1) | WO2017111979A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105801653B (zh) * | 2014-12-30 | 2018-04-17 | 苏州晶云药物科技有限公司 | 奥贝胆酸的晶型a及其制备方法 |
WO2018211413A1 (fr) * | 2017-05-15 | 2018-11-22 | Dr. Reddy’S Laboratories Limited | Formes solides d'acide obéticholique et procédé de préparation associé |
CN109280071A (zh) * | 2017-07-19 | 2019-01-29 | 东莞东阳光药物研发有限公司 | 奥贝胆酸的晶型及其制备方法 |
CN107383139A (zh) * | 2017-08-09 | 2017-11-24 | 杭州和泽医药科技有限公司 | 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法 |
CZ31099U1 (cs) * | 2017-09-05 | 2017-10-17 | Zentiva, K.S. | Krystalické formy (3a,5B,6a,7a)-6-ethyl-3,7- dihydroxycholan-24-ové kyseliny |
CN109485687A (zh) * | 2017-09-12 | 2019-03-19 | 成都弘达药业有限公司 | 奥贝胆酸的晶型j及其制备方法 |
WO2019106043A1 (fr) | 2017-11-29 | 2019-06-06 | Hexal Ag | Composition pharmaceutique comprenant de l'acide obéticholique |
GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
CN113264972B (zh) * | 2020-02-14 | 2024-07-12 | 四川科伦药物研究院有限公司 | 一种制备奥贝胆酸的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20050912A1 (it) * | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
AU2013277429B2 (en) * | 2012-06-19 | 2016-01-14 | Intercept Pharmaceuticals, Inc. | Preparation, uses and solid forms of obeticholic acid |
WO2016045480A1 (fr) * | 2014-09-28 | 2016-03-31 | 上海源力生物技术有限公司 | Procédé de préparation d'acide obéticholique |
EP3221334B1 (fr) * | 2014-11-19 | 2020-02-19 | Nzp Uk Limited | Stéroïdes 6.alpha.-alkyl-6,7-dione utilisés en tant qu'intermédiaires pour la production de modulateurs de fxr stéroïdiens |
TWI686400B (zh) * | 2014-11-19 | 2020-03-01 | 英商Nzp英國有限公司 | 化合物(二) |
KR102546748B1 (ko) * | 2014-11-19 | 2023-06-22 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드 |
PL3221331T3 (pl) * | 2014-11-19 | 2020-03-31 | NZP UK Limited | Steroidy, 6-alkilo-7-hydroksy-4-en-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr |
-
2016
- 2016-01-08 EA EA201891491A patent/EA201891491A1/ru unknown
- 2016-01-08 BR BR112018012590A patent/BR112018012590A2/pt not_active Application Discontinuation
- 2016-01-08 CA CA3009149A patent/CA3009149A1/fr not_active Abandoned
- 2016-01-08 EP EP16714049.0A patent/EP3394081A1/fr not_active Withdrawn
- 2016-01-08 MX MX2018007776A patent/MX2018007776A/es unknown
- 2016-01-08 WO PCT/US2016/012651 patent/WO2017111979A1/fr active Application Filing
- 2016-01-08 KR KR1020187020850A patent/KR20180095070A/ko unknown
- 2016-01-08 SG SG11201805235XA patent/SG11201805235XA/en unknown
- 2016-01-08 JP JP2018532396A patent/JP2018538331A/ja active Pending
- 2016-01-08 CN CN201680079793.8A patent/CN108495858A/zh active Pending
- 2016-01-08 AU AU2016375566A patent/AU2016375566A1/en not_active Abandoned
-
2018
- 2018-06-13 IL IL259998A patent/IL259998A/en unknown
- 2018-06-20 PH PH12018501318A patent/PH12018501318A1/en unknown
- 2018-06-22 CL CL2018001720A patent/CL2018001720A1/es unknown
- 2018-06-27 CO CONC2018/0006701A patent/CO2018006701A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016375566A1 (en) | 2018-07-05 |
PH12018501318A1 (en) | 2019-02-18 |
MX2018007776A (es) | 2018-08-09 |
CN108495858A (zh) | 2018-09-04 |
IL259998A (en) | 2018-07-31 |
KR20180095070A (ko) | 2018-08-24 |
EP3394081A1 (fr) | 2018-10-31 |
SG11201805235XA (en) | 2018-07-30 |
WO2017111979A1 (fr) | 2017-06-29 |
JP2018538331A (ja) | 2018-12-27 |
EA201891491A1 (ru) | 2018-11-30 |
CL2018001720A1 (es) | 2018-08-10 |
CO2018006701A2 (es) | 2018-07-10 |
BR112018012590A2 (pt) | 2018-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018241172B2 (en) | Preparation, uses and solid forms of obeticholic acid | |
CA3009149A1 (fr) | Formes cristallines polymorphes de l'acide obeticholique | |
US9982008B2 (en) | Preparation and uses of obeticholic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20220329 |
|
FZDE | Discontinued |
Effective date: 20220329 |